PMID- 22382148
OWN - NLM
STAT- MEDLINE
DCOM- 20120730
LR  - 20211021
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Print)
IS  - 0269-9370 (Linking)
VI  - 26
IP  - 8
DP  - 2012 May 15
TI  - T-cell activation and neurodevelopmental outcomes in perinatally HIV-infected 
      children.
PG  - 959-69
LID - 10.1097/QAD.0b013e328352cee7 [doi]
AB  - OBJECTIVE: To evaluate baseline T-cell activation and neurodevelopmental outcomes 
      over time in a cohort of perinatally HIV-infected (PHIV-infected) children with 
      severe disease. DESIGN: Pediatric AIDS Clinical Trials Group protocol 366 (PACTG 
      366) was a partially randomized, open-label, multicenter 96-week antiretroviral 
      treatment-algorithm study. Neurodevelopmental status, measured by age-dependent 
      evaluations (Bayley scales of infant development-II; Wechsler preschool and 
      primary scale of intelligence-revised; Wechsler intelligence scale for 
      children-III), was a secondary outcome. METHODS: Linear mixed models were used to 
      assess the baseline and follow-up neurodevelopmental outcomes in relation to 
      immune activation, measured by CD38 and human leukocyte antigen (HLA) DR 
      expression on peripheral CD4(+) and CD8(+) T cells at study baseline. Models were 
      adjusted for age, sex, race/ethnicity, baseline viral load, baseline CD4%, 
      cytomegalovirus (CMV) infection status at entry, study treatment arms, central 
      nervous system penetrance score of antiretroviral regimen at entry, and viral 
      load response 16 weeks postentry. RESULTS: Among 126 PACTG 366 enrollees who were 
      at least 1 year old and had both immune activation and age-appropriate 
      neurodevelopmental assessments at baseline, 80 (63%) were black non-Hispanic, 71 
      (56%) males, 122 (97%) were on antiretrovirals, and 45 (36%) were in Centers for 
      Disease Control and Prevention (CDC) disease category C at entry. 
      CD4(+)CD38(+)HLADR(+)%, CD4(+)CD38(-)HLADR(+)%, and CD8(+)CD38(+)HLADR(+)% were 
      positively associated with full-scale Intelligence Quotient scores (FSIQ) (slope 
      = 0.18, 0.70, and 0.15, respectively; P = 0.02, 0.03, and 0.04, respectively). 
      CD4(+)CD38(+)HLADR(-)% was negatively associated with FSIQ (slope =  -0.16, P = 
      0.01). CONCLUSION: Contrary to HIV-infected adults, in PHIV-infected children 
      higher CD4(+)CD38(+)HLADR(+)% may be associated with a neuroprotective effect and 
      higher percentage of CD4(+)CD38(+) but HLADR(-) T cells may be deleterious.
FAU - Kapetanovic, Suad
AU  - Kapetanovic S
AD  - National Institutes of Health, National Institute Mental of Health, Bethesda, 
      Maryland, USA. suad.kapetanovic@nih.gov
FAU - Aaron, Lisa
AU  - Aaron L
FAU - Montepiedra, Grace
AU  - Montepiedra G
FAU - Burchett, Sandra K
AU  - Burchett SK
FAU - Kovacs, Andrea
AU  - Kovacs A
LA  - eng
GR  - HHSN267200800001G/DK/NIDDK NIH HHS/United States
GR  - U01 AI068632/AI/NIAID NIH HHS/United States
GR  - UM1 AI068632/AI/NIAID NIH HHS/United States
GR  - U01 AI068616/AI/NIAID NIH HHS/United States
GR  - HHSN267200800001C/HD/NICHD NIH HHS/United States
GR  - U01 AI041110/AI/NIAID NIH HHS/United States
GR  - N01-DK-9-001/HHSN267200800001C/DK/NIDDK NIH HHS/United States
GR  - AI068632/AI/NIAID NIH HHS/United States
GR  - 1 U01 AI068616/AI/NIAID NIH HHS/United States
GR  - 5 U01 AI41110/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (HLA Antigens)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1/metabolism
MH  - Adolescent
MH  - Antiretroviral Therapy, Highly Active
MH  - CD4-Positive T-Lymphocytes/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Central Nervous System Diseases/*complications
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Follow-Up Studies
MH  - HIV Infections/*complications/drug therapy
MH  - HLA Antigens/metabolism
MH  - Humans
MH  - Infant
MH  - Male
MH  - Time Factors
PMC - PMC3437925
MID - NIHMS390595
COIS- Conflicts of interest There are no conflicts of interest.
EDAT- 2012/03/03 06:00
MHDA- 2012/07/31 06:00
PMCR- 2012/09/10
CRDT- 2012/03/03 06:00
PHST- 2012/03/03 06:00 [entrez]
PHST- 2012/03/03 06:00 [pubmed]
PHST- 2012/07/31 06:00 [medline]
PHST- 2012/09/10 00:00 [pmc-release]
AID - 10.1097/QAD.0b013e328352cee7 [doi]
PST - ppublish
SO  - AIDS. 2012 May 15;26(8):959-69. doi: 10.1097/QAD.0b013e328352cee7.